Our results aid the examination of growth factor‐mediated EV release in pathological conditions, where EVs contribute to the progression of neurodegenerative diseases, such as Parkinson's disease (PD) or Alzheimer's disease (AD).93, 94, 95, 96, 97 Furthermore, our results will promote the investigation of EV‐associated changes in responses to neuronal injury48, 49, 50 or psychiatric conditions where bFGF has been shown to be strongly implicated (reviewed in refs. 51, 52). Here, FGF2 is linked to early-onset autosomal dominant Alzheimer disease.